Sarpeta
FDA approves Sarepta rival NS Pharma’s Duchenne drug
Drug approved for patients with exon 53 mutation
FDA sets Q3 decision date for NS Pharma’s DMD drug
If approved it will become second-to-market after Sarepta
Sarepta rival NS Pharma files Duchenne drug with FDA
Another blow for Sarepta following FDA rejection earlier this year